Navigation Links
Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:5/16/2008

MicroRNAs as Potential Biomarkers -- for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary

(CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer

Results of microRNA Signature to Identify Tissue Origin Demonstrate

Accuracy Exceeding 90% and Specificity of 99%

REHOVOT, Israel and JERSEY CITY, New Jersey, May 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois.

Presented posters:

1. "MicroRNA signature identifies tissue origin of primary and metastatic tumors"; Tuesday, June 03, 8:00AM - 12:00PM; Hall S102a, abstract # 11028.

Each year approximately 70,000 patients in the United States are diagnosed with cancer of unknown primary (CUP). Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions. Rosetta Genomics' scientists have designed a classifier which assigns a primary site to a cancer sample based on the microRNA expression in the sample. The overall sensitivity of this classifier is approximately 85%, with two-thirds of the samples being classified with high-confidence, reaching accuracy exceeding 90% and specificity of 99%.

2. "Differential microRNA expression in pleural mesothelioma: Implications
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... Invuity, a leading developer of state-of-the-art illuminated surgical ... at the American College of Surgeons, 97th Annual ... specifically for breast mastectomies, lumpectomies, sentinel node biopsies ... proprietary Eigr ™ (pronounced eye-gr) illumination technology ...
... Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ) announced ... conference call for late November.  The purpose of the ... (i) the status of the Company,s efforts in respect ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), (ii) financing ...
Cached Medicine Technology:Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 2Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
(Date:8/2/2014)... According to the Girl Gets Ring System review ... for women. The book consists of dating tips and tricks ... book also teaches women how to deal with relationship ... its review that this book is divided into 10 chapters ... Story? ,     Chapter 2 – How A Traffic Light ...
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health ... settle the class action lawsuit filed October 24, ... 24-C-13-001041 MM, on behalf of thousands of women who allegedly ... According to The Baltimore Sun , the $190 ... a physician accused of sexual misconduct. , An investigation prompted ...
(Date:8/1/2014)... The successful development of C60F projects is of ... Automobile Co.,LTD. As early as the very beginning of ... excellent team to develop a comprehensive plan to carry ... The company’s vice president Liming Yang and some of ... the specific arrangement and the supervision of the project ...
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
... Oncotype DX™ is a diagnostic assay that ... in women with newly diagnosed, early stage ... disease recurrence, Oncotype DX also assesses the ... assay performed using formalin-fixed, paraffin-embedded tumor ...
... HER2 FISH pharmDx Kit is a direct ... to quantitatively determine HER2 gene amplification in ... amplification is determined from the ratio between ... of the HER2 gene probe (red signals) ...
... age of 3 can choose either the PARI ... design principle applies to both:, ,Maximize aerosol ... output when the patient exhales using two one-way ... leave the nebulizer. The result is a high ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
Medicine Products: